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1. Introduction 
The expansion of the modern pharmacopeia is driven by advances in structural genomics 
that enable the detailed understanding of drug – protein interactions necessary for the 
identification of novel compounds as well as improved variants of existing drugs. Our 
research has centered on understanding the mechanism by which a critical class of 
transmembrane receptor proteins, the integrins, become activated in healthy and disease 
states. An important component of this research has been in identifying novel inhibitors of 
integrin function and their mechanism of action. As we describe in the following sections, 
nuclear magnetic resonance spectroscopy (NMR) has been an essential tool in advances in 
this area, and is the major focus of this review.  
Integrins are a family of cell surface receptor proteins that mediate cell-matrix and cell-cell 
adhesion (Hynes, 2002). Integrin mediated adhesion is critical in multiple phases of 
development and maintenance of tissue physiology. Conversely, aberrant integrin function 
that can arise due to inappropriate increase or decrease in expression levels as well as 
inappropriate levels of activation is implicated in many diseases including cancer, neurological 
and immunological disorders (Shimaoka and Springer, 2003). The critical role of integrins in 
maintenance of healthy physiology has stimulated intense efforts to understand the 
mechanism of integrin mediated adhesion and identify pharmacological agents that can alter 
integrin function and thus restore the appropriate levels of cellular adhesion. Although the 
focus of this review is on NMR spectroscopy, as opposed to the related technique of magnetic 
resonance imaging (MRI), many of the compounds identified as integrin antagonists are also 
of interest as probes for MRI, particularly in the area of cancer imaging (Dijkgraaf et al., 2009). 
Thus, although we confine ourselves to understanding the interactions between antagonists 
and integrins by NMR in vitro, many of these results are directly applicable to the study of 
integrin expression and function by MRI in vivo. 
Nuclear magnetic resonance (NMR) spectroscopy has played a central role in understanding 
the mechanism of integrin activation and providing insight into the nature and dynamic 
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consequences of known small molecule modulators of integrin function (Beglova et al., 
2002; Kallen et al., 1999). However, integrins are large (~2 megadalton), poly-glycosylated, 
membrane-associated receptor proteins and NMR studies of systems of such complexity 
are exceptionally challenging. Fortunately, (at least some of) the ecto- domains of the 
integrin heterodimer can be expressed in the absence of the transmembrane segments and 
retain ligand binding function and specificity (Xiong et al., 2007). In particular, the ligand 
binding I-domain, is found in half of all vertebrate integrins and can be expressed (and 
isotope labeled) using conventional bacterial over-expression systems (Kriwacki et al., 
2000; Lambert et al., 2008; Legge et al., 2000). Many potent integrin antagonists that target 
the I domain have been developed drawing on the structural insights of NMR 
investigations into I-domain : antagonist structure, and this remains an active and  
promising  area of research (Constantine et al., 2006; Crump et al., 2004; Liu et al., 2001; 
Winn et al., 2001; Weitz-Schmidt et al., 2001). 
Although there has been great progress in understanding integrin biology using 
recombinantly expressed fragments, there is also considerable interest in studying the 
regulation of integrin function in situ. Integrins are regulated by signals originating both 
outside and within the cell on which they are expressed and a pure in vitro system can-not 
fully recapitulate the complex dynamics of cellular signaling. The large size and 
transmembrane linkage limits the use of routine solution experiments for NMR observation 
of the integrin in the native environment. However, techniques described in this review, 
including saturation transfer difference NMR (STD-NMR), allow for a detailed investigation 
into the binding mechanism from the perspective of the ligand (Mayer and Meyer, 1999). 
Although the integrin is not directly observed in these techniques, these investigations 
bridge the gap between structural studies of integrin ligands in solution by NMR and high-
resolution structures of integrins obtained both by crystallography and advanced modeling 
techniques (Wagstaff et al., 2010b; Claasen et al., 2005; Meinecke and Meyer, 2001). These 
methods are useful both in large scale screening programs and also to understand 
conformational changes in ligands associated with integrin binding. 
2. Integrin function in physiology and disease 
Integrins are a family of metazoan specific transmembrane proteins that mediate cell 
adhesion (intercellular and cell-matrix) and transmit signals associated with attachment 
into the cell (Hynes, 2002). Integrins are expressed on all cell types and have a panoply of 
physiological roles in development, as evidenced by the dramatic phenotype(s) observed 
in transgenic knock-out models of many integrins or their protein ligands e.g. (George et 
al., 1993; Yang et al., 1993). Some integrins, though less critical during development, are 
absolutely required for survival of the mature organism. For example, knockout of the 
leukocyte restricted integrin LFA-1 results in pronounced but selective immune deficits, 
underscoring the importance of LFA-1 in multiple phases of the immune response (Ding 
et al., 1999).  
Integrins can rapidly up and down regulate their affinity for ligands from the basal to fully 
activated state (Shamri et al., 2005). This differs from other adhesion molecules that require 
changes in cell surface expression and in-membrane diffusion to modulate the adhesive 
properties of the cells on which they are expressed. Cells utilize the dynamic nature of 
integrin adhesion to dynamically modulate their interaction with the surrounding 
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environment on a timescale much shorter than possible with other cell adhesion molecules. 
Conversely, the dynamic nature of integrin-mediated adhesion requires a precision 
regulatory apparatus since even small perturbations in integrin activity regulation can have 
pronounced effects. This is strikingly evident in murine transgenics in which constitutively 
active variants are ‘knocked-in’ to replace the normal wild-type variants. These knock-in 
mice display phenotypes often as severe as the transgenic knock-out of the same gene (Imai 
et al., 2008; Park et al., 2007; Semmrich et al., 2005). 
Each integrin is formed from the non-covalent association of 1 of 18 alpha subunits and 1 of 
8 beta subunits with 24 known combinations expressed on mammalian cells excluding splice 
variants (Hynes, 2002). For example, the integrin LFA-1 is formed from the alphaL subunit 
and the beta2 subunit, designated L2. A third commonly encountered nomenclature is the 
cluster of differentiation where LFA-1 is designated CD11a/CD18. The integrin Mac-1, 
found predominantly on neutrophils, is formed from the common beta2 (CD18) subunit but 
uses the CD11b alpha chain and is designated as M2 or CD11b/CD18. The complete array 
of mammalian integrins is shown in FIGURE 1. 
Each integrin has a unique, but overlapping, ligand binding profile (Campbell and 
Humphries, 2011). Most integrin ligands are extracellular matrix molecules including 
fibronectin, vitronectin and collagen. Other ligands are cell surface proteins, such as the 
Intercellular Adhesion Molecules (ICAMs). A canonical recognition motif for many integrins 
is Arg-Gly-Asp (RGD), with residues flanking either end of the triplet responsible for 
specifying the correct conformation to bind to distinct integrins (Ruoslahti, 1996). Other 
integrins recognize unique motifs found in a select group of  protein(s). While many 
integrins do not recognize the RGD motif, an acidic moiety is a common feature of all 
integrin ligands (Plow et al., 2000).  
 
Fig. 1. Integrin subunit combinations. 18 alpha and 8 beta subunits form 24 integrin 
heterodimers. Asterisks denote alpha subunits containing an inserted (I) domain.  
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Integrins are involved in all aspects of mammalian physiology. It is not surprising that 
integrins are also involved in the pathogenesis of numerous diseases. Integrins involvement 
in disease initiation and progression may result either via direct perturbation of integrin 
expression or function. Alternatively, integrin function may be exploited to   circumvent 
ordinary protection against disease physiology. One of the central challenges of 
pharmacology is to selectively alter integrin function that promotes the disease state in the 
much greater background of normal integrin activity (Shimaoka and Springer, 2003).  
Cancer: Several Integrins play a crucial role in cancer development and the specific integrins 
varies depending upon the primary origin of the cancer (Jin and Varner, 2004). Down 
regulation of integrin expression is required to migrate to secondary tissues as well as 
establish a secondary site of growth. The high metabolic needs of cancer cells also requires 
extensive angiogenesis, the growth of blood vessels. Two V integrins (V3 and V8) 
have received considerable interest due to their role in cell survival and promoting 
angiogenesis(Nemeth et al., 2007). Appreciation of the critical role of these integrins in 
cancer has led to the development of inhibitors targeting V integrins as chemotherapeutics. 
One example, the cyclic RGD-f(NMet) peptide, is currently in clinical trials for glioblastoma 
(Reardon et al., 2008).  
Thrombosis: Integrin IIb3 binding to ligand fibrinogen is required for the process of 
blood clot formation. Aberrant clot formation is occurring within blood vessels is called 
thrombosis, a life-threatening condition (Coller and Shattil, 2008). Thrombosis may be 
treated with drugs such as eptifibtide, a cyclic peptide derived from a snake venom 
protein barbourin with a KGD sequence that acts as an IIb3 competitive antagonist 
(Scarborough, 1999).  
Autoimmunity: Integrins play multiple roles within the immune system including mediating 
migration to and from the source of infections, stabilizing contacts between immune cells, 
delivering key co-stimulatory signals required for immune cell development and function, 
as well as mediating opsonization of foreign organisms (Evans et al., 2009). Autoimmune 
disorders, including multiple sclerosis, psoriasis and colitis, involve physiological integrin 
function being co-opted by dysfunctional immune cells, facilitating the propagation of 
disease. Developing selective inhibitors of leukocyte expressed integrins, particularly the 2 
family and the 4 integrins is a major focus of anti-inflammatory effector research 
(Shimaoka and Springer, 2003).  
Infection: Although integrin function is obligate for normal immune homeostasis, several 
integrins are also exploited for the establishment and maintenance of several diseases. 
Integrins act as receptors or co-receptors for several viruses, including paploma virus (64) 
(Yoon et al., 2001), rotavirus (21 and 41) (Fleming et al., 2007), Ebola virus (51) 
(Schornberg et al., 2009) and adenoviruses (Cuzange et al., 1994). These interactions may be 
with the canonical ligand binding regions or with other regions of the integrins, a critical 
consideration in the design of selective inhibitors of pathogen – intergrin interactions. Some 
integrins may also facilitate the formation of a virological synapse and promote the spread 
of lentiviruses such as HIV (Cicala et al., 2011). 
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3. Integrin structure 
Both  and  integrin subunits are complex, multidomain single-span type-I transmembrane 
glycoproteins with short (but critical) cytoplasmic sequences excluding 4 which has a large 
intracellular domain (FIGURE 2A-C). High-resolution structural techniques including x-ray 
crystallography, cryo-electron microscopy (cryo-EM) and NMR spectroscopy have 
converged on a model of the individual integrin domains and their role in the transition 
from inactive to active state. Of particular importance is the high level of sequence 
conservation within the integrin family, such as the location and number of critical 
disulphide bonds (Luo et al., 2007). Thus, although high-resolution structures have only 
been obtained for two intact members of the 3 family and a single 2 integrin, the 
structural insights gained are applicable to other integrins (Xie et al., 2004; Xiong et al., 
2001).  
 
Fig. 2. Integrin structures and domains and conformational changes. (A-C) Global 
conformational changes between the bent (A), intermediate (B), and extended (C) 
conformations. Blow-ups showing the structures of the high- and low-affinity conformations 
of the alpha I domains (D). A piston-like downward shift of the C-terminal helix (arrow 1) is 
allosterically linked to the conversion of the MIDAS to the high-affinity configuration 
(arrow 2). Superposition of the high- (blue) and closed low- (yellow) affinity I domains is 
shown. Regions undergoing significant conformational changes are colored, whereas 
regions not undergoing significant conformational changes are in gray. 
3.1 Extracellular domain 
3.1.1 -subunit 
Integrin alpha subunits are organized in 4 or 5 domains and are approximately 1000 amino 
acids in length. The N-terminus forms a -propeller with each strand of the propeller 
formed from a 4-stranded antiparallel -sheet. C-terminal to the -propeller is the thigh, 
calf-1 and calf-2 domains, all -sandwich domains that bear topological similarity with 
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immunoglobin domains. A short disulphide bonded loop, the genu, is positioned between 
the thigh and calf-1 domains; the genu can form a calcium coordinating site although this is 
not observed in all integrins (Xie et al., 2004). A furin protease cleavage site, located in calf-2 
that separates the alpha subunit into light and heavy chains is found in a subset of integrins 
(3, 5, 6, 8, V, and IIb) (Campbell and Humphries, 2011).  
In half of all mammalian integrin subunits (1, 2, 10, 11, L, X, M, D, E) an 
additional domain is inserted between blades 2 and 3 of the -propeller. When present the 
Inserted (I-) domain forms all or part of the ligand-binding site (Shimaoka et al., 2002). 
Multiple crystal, and one NMR structure, have been determined of isolated I domains 
from several integrins. The I-domain is built from seven -helices wrapping five parallel 
and one anti-parallel strands that generally alternate in the protein sequence. On the ‘top’ 
face of the I domain, five amino acids side chains form a divalent cation binding site (the 
metal ion dependent adhesion site, MIDAS) (Lee et al., 1995b; Qu and Leahy, 1995). A ring 
of hydrophobic residues (the hydrophobic cup) surrounds the MIDAS site (Shimaoka et 
al., 2002). The N- and C- termini of the I domain are in close proximity and form flexible 
linkers to the -propeller, as revealed in a recent crystal structure of the integrin X2 (Xie 
et al., 2004).  
The I domain from integrin M crystallizes in two conformations, termed open and closed 
(Lee et al., 1995a; Lee et al., 1995b). The two conformations, which are thought to represent 
endpoints of a conformational continuum, differ in the coordination sphere surrounding the 
MIDAS (FIGURE 2D). In the open conformation, one of the acidic residues coordinating the 
metal is replaced by a water molecule, the effect of which is to increase the electrophilicity of 
the metal. Since physiological integrin ligands contain acidic residues, reorganization of the 
MIDAS promotes ligand binding, as does the repositioning of loops on the top face that 
occurs in the open state. Also, in the open conformation the C-terminal helix is shifted 
downward by approximately two turns with respect to the position in the closed 
conformation. It is thought that conformational changes C-terminal helix acts as an allosteric 
switch regulating the conformation of the ligand binding face, a hypothesis that is 
supported by additional biochemical evidence and computer simulations (Jin et al., 2004; 
Xiong et al., 2000).  
Unlike M, the I domain from L does not crystallize naturally in the open conformation; 
this is consistent with the observation that the isolated wild-type M I domain retains 
affinity for ligand while the I domain from L does not (Lu et al., 2001b; Qu and Leahy, 
1995). However, using the open structure of M as a template, is has been possible to 
engineer disulphide bonds in the L sequence that stabilize the conformation of the open 
state (Lu et al., 2001a). Locking the L I domain in the open conformation results in a 104 
increase in affinity for ligand. In a co-crystal of the high affinity L I domain with a two 
domain fragment of the ligand Intracellular Adhesion Molecule-1 (ICAM-1-D1D2), the C-
terminal helix is found in the (expected) downward conformation and the ligand binding 
face, including the MIDAS, has undergone the appropriate conformational changes to 
facilitate binding to ligand. A number of polar and electrostatic interactions adjacent to the 
hydrophobic cup (and absent in M) confer specificity of the I-domain : ICAM-1 interaction 
(Shimaoka et al., 2003).  
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The  subunits are ~640 amino acids in length, organized into 8 discrete extracellular 
domains. The N-terminus is a 54 residue, 2 stranded antiparallel -sheet linked by 
disulphide bonds to pair of short  helices. The structure is homologous to the plexins and 
semaphorins and is thus called the Plexin-semaphorin-integrin (PSI) domain. Notably, the 
fourth disulphide bond is actually to a stretch of amino acids C-terminal to the adjacent 
hybrid domain, an immunoglobulin – like structure, such that the hybrid domain is inserted 
within the PSI domain (Luo et al., 2007). 
Inserted within the hybrid domain is the A or I – like domain, which is structurally 
homologous to the I-domain found in half of mammalian integrin  subunits. The peculiar 
topology of the I-like domain, a domain inserted into a domain inserted into a domain, is 
critical for the mechanism of integrin activation. In addition to the MIDAS, there are two 
additional coordination sites whose occupancy regulates the affinity of the MIDAS metal for 
ligand through shared coordination residues. These two metal binding sites (the Adjacent to 
MIDAS, ADMIDAS, and Ligand Induced Biniding Site, LIMBS) may also selectively directly 
coordinate some ligands (Xiao et al., 2004; Xiong et al., 2002).  
The residues C-terminal to the I-like domain are organized into four- cysteine rich 
Epidermal Growth factor like (EGF) domains. The integrin-EGF (I-EGF) domains are highly 
homologous to the canonical domain but have additional numbers and/or placements of 
the disulphide bonds (Beglova et al., 2002; Takagi et al., 2001; Wouters et al., 2005). The most 
C-terminal ecto domain is the -terminal domain (TD), a novel fold with an N-terminal 
helix facing a mixed parallel/antiparallel -strand. 
Transmembrane: The transmembrane (TM) domains of integrins form a critical nexus 
between the extracellular and intracellular domains. Despite the great importance of the 
domains to the mechanism of integrin mediated adhesion and signaling, they are the least 
well-understood domains of integrin heterodimers. NMR of isolated transmembrane 
domains (in detergent solutions), disulphide cross-linking studies and molecular modeling 
studies have been used to identify the interface between the two chains. These studies 
converge on a right-handed coil-coil structure, which persists into the cytoplasm, similar to 
the previously determined structure of the TM protein glycophorin (Gottschalk, 2005; Li et 
al., 2002; Luo et al., 2004).  
Cytoplasmic: Integrin cytoplasmic domains play a role in integrin function that is 
disproportionate to their generally small size. Interactions between the  and  cytoplasmic 
domains help constrain integrins in the inactive conformation (Vinogradova et al., 2002). 
Phosophorylation of the cytoplasmic domains regulates indirect interactions with the 
cytoskeleton and protein signaling complexes (Fagerholm et al., 2004). The cytoplasmic tail 
complexes of two integrins, IIb3 and L2 have been extensively studied by NMR 
(Vinogradova et al., 2002). The IIb tail forms a short N-terminal a helix followed by a turn 
and a C-terminal loop that collapse back onto the N-terminal helix. The 3 tail also forms an 
N-terminal helix while the majority of the tail lacks persistent structure. A salt bridge 
between residue arginine 995 in the IIb chain (R-995) forms with the aspartic acid 723 in 
the 3 tail (D-723). Prior biochemical studies of integrins using heterologous expression 
suggested the existence of a stabilizing salt bridge interaction as a critical element in 
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regulating the affinity state of integrins (Lu et al., 2001c). Notably, the cytoplasmic tail 
structure of the integrin L2, also determined by NMR, is significantly different (Bhunia et 
al., 2009). The L is folds into three defined -helical segments with compact tertiary 
structure and the 2 tail into a single helix followed by unstructured segments. Like the 
IIb3 tail complex, the L2 association incorporates a prominent electrostatic interaction. 
Both similarities and differences in the two structures highlight the strengths, but also 
limitations, of extrapolating limited structural studies of one integrin to another, particularly 
in regions of lower sequence homology such as the tail domains.  
4. Architecture and activation mechanism 
Overall, in both  and  chains the integrin architecture can be divided into distinct 
structural elements. The integrin “head”, which includes the canonical ligand-binding site, 
is formed from the -propeller in the -subunit and the I-like domain in the - subunit. In a 
subset of integrins, the Inserted (I-) domain is also present in the integrin head. The 
headpiece includes both the head domains as well as the thigh domain in the  chain and 
the plexin-semaphorin- integrin (PSI), and hybrid domains in the  subunit. The tailpiece is 
formed in the alpha subunit by the calf -1 and calf-2 domains and 4 integrin-type epidermal 
growth factor like (I-EGF) domains in the  subunit. The tailpiece is connected to the 
transmembrane domains which each span the membrane a single time and the (generally) 
short cytoplasmic sequences.  
In the crystal structure of V3, the integrin is folded into a ‘V ‘shape; a 135 degree angle is 
found between the head and tailpiece domains with a bend between the thigh and calf-1 
domains in the alpha subunit and the I-EGF-1 and I-EGF-2 in the beta subunit. Although 
neither the transmembrane, nor the cytoplasmic domains are present in the crystallized 
proteins, they are generally regarded as being fully associated in the conformation 
visualized in the crystal structure. In this conformation, which establishes substantial inter 
and intradomain buried interfaces, the ligand-binding headpiece is inaccessible to ligands 
on opposing surfaces (Xiong et al., 2001). 
Integrins that lack I-domains use an interface between the -propeller and the I –like domain 
to form the ligand-binding site. The architecture of a canonical ligand binding motif was first 
identified in a crystal structure of the integrin V3 with P5, a RGD containing cyclic peptide 
[Arg-Gly-Asp-{D-Phe}-N-methyl-Val} (Xiong et al., 2002). P5 binds within a crevice formed 
from the -propeller and the A domain; 335 Å, or 45% of the peptide surface area, is buried 
within the crevice. In the bound structure, the arginine and aspartic acid are pointed in 
opposite directions, the (partially solvent exposed) Arg pointing towards the-propeller, 
inserted into a narrow sub-groove where it is stabilized by a pair of aspartic acids that form a 
bidentate salt bridge. The Asp is fully buried with one of the carboxylates coordinating the 
MIDAS metal; the second oxygen establishes a network of polar interactions with backbone 
amides and the aliphatic side chain makes additional hydrophobic contacts with protein side 
chain. The medial glycine sits at the / interface, making hydrophobic contacts with the  
chain. Both of the non-RGD residues are purely structural, establishing the correct disposition 
of the RGD and point away from the / interface. 
The crystal structure of ligand bound integrins reveal a number of structural changes in the 
 chain I –like domain that are analogous to those that occur during activation of the I 
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domain. The 6-7 loop is repositioned and the C-terminal helix is shifted downward in a 
piston like motion. Subsequent structures reveal how ligand binding is coupled to activation 
of the holoreceptor (Xiao et al., 2004). Ligand binding to the II3 headpiece crystal 
structure shows a profound swing out motion of the hybrid domain/PSI, away from the  
interface where the hybrid domain is tucked in the resting conformation. This motion 
propagates changes in the ligand-binding headpiece to the remainder of the integrin, and is 
a critical element of the switchblade model of integrin activation.  
The switchblade model of integrin activation states that the integrin is in a conformational 
equilibrium between the bent state, observed in the crystal structure of V3 and an 
extended conformation (or conformations) in which legs become separated and the 
headpiece becomes extended over the tailpiece (Luo et al., 2007). In this extended 
conformation, the headpiece is well disposed to bind ligands in the extracellular matrix or 
on the surface of opposing cells. Extension also favors dissociation of the transmembrane 
and cytoplasmic, facilitating the formation of signaling complexes on the tails. Integrin 
activation is bidirectional and can be driven either by ligand binding to the headpiece, 
favoring a swung out hybrid domain which in turn disrupts the stabilizing interfaces and 
favors receptor extension. Alternatively, activation may occur within the cell via binding of 
transiently exposed cytoplasmic tails which, stabilized in the dissociated conformation, can 
initiate conformational changes that propagate across the membrane, resulting in extension, 
swing out of the hybrid domain and an integrin primed for ligand binding.  
In integrins that have an I domain in the a subunit (i.e. L2), there is a conserved acidic 
residue in the linker connecting the C-terminal tail back into the -propeller (Alonso et al., 
2002). When the C-terminal helix is shifted downward, the acidic residue can coordinate the 
 subunit MIDAS metal. The downward motion of the C-terminal helix thus transmits the 
effect of ligand binding to the I domain across the / subunit interface with the acidic 
residue acting as an internal ligand. The subsequent steps of integrin activation are identical 
for both classes of integrins (Nishida et al., 2006).  
5. NMR overview 
NMR spectroscopy is an extensively used tool for the structural and dynamic 
characterization of proteins, small molecule ligands and their complexes. An exhaustive 
review of NMR theory and methodology is available in many organic and biological 
chemistry texts (e.g. (Cavanagh et al., 2006; Ege, 2003)); here, we selectively present 
information salient for understanding (and interpreting) published and future work on 
integrin and integrin – antagonist complexes. 
NMR spectroscopy draws on quantum mechanical property of spin, the polarization of a 
subset of nuclear isotopes when placed in a magnetic field. This includes all three isotopes 
of hydrogen, the most abundant element in biomolecules. However, only the spin ½ nuclei – 
such as the 1H (proton) nucleus is commonly studied by NMR. 2H (deuterium) is a spin 1 
nucleus; nuclei with spin >1/2 are generally low sensitivity and difficult to observe in 
solution. The radioactive 3H (tritium) nucleus is not commonly observed, despite being spin 
½ and the most sensitive NMR active nucleus. Fortunately, both carbon (13C) and nitrogen 
(15N) have a spin ½ isotope, albeit at low natural abundance (~1 % and ~0.4 % respectively). 
To utilize these nuclei for biomolecular investigations it is necessary, in general, to increase 
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the enrichment levels. This can be accomplished by expressing proteins in organisms, 
typically Escherichia coli, that can grow in defined media containing appropriate isotopic 
precursors (i.e. 15N labeled ammonium chloride, 13C labeled glucose). Unfortunately, there is 
no spin ½ nucleus of oxygen, precluding direct observation in proteins and studies of 
hydrogen bonding in protein – ligand studies.  
NMR experiments involve the perturbation of the equilibrium spin state by one or more 
appropriately tuned radio-frequency pulses and interspersed delay periods. This collection 
of pulses and delays is called a pulse sequence. A pulse sequence may be as simple as a 
single pulse applied to a single nucleus or involve hundreds of pulses and delays applied to 
as many as four nuclei. In both extremes, the resulting spectra (derived as the Fourier 
transform of the time dependent signal obtained by the NMR detector) are determined by 
the same set of three interactions: (1) chemical shift, (2) scalar (J-coupling) and (3) dipolar 
coupling that modulate the energy levels of the nuclear spins during the NMR experiment. 
Local variations in electronic structure within the molecule result in the nucleus becoming 
more or less shielded from the spectrometer magnetic field, giving rise to small differences 
in nuclear magnetic energy levels. This phenomenon is known as the chemical shift and is 
the most readily observed effect in the NMR spectrum. Each peak in the NMR spectrum 
corresponds to the single type of nucleus in the molecule. Because each nucleus has a 
distinctive chemical shift, it is possible to obtain site-specific information throughout the 
molecule with the chemical shift of a particular nucleus acting as its molecular signature.  
The J- coupling is an interaction between (directly or indirectly) covalently bonded NMR 
active nuclei. In the simple, one dimensional (1D) NMR experiment, the J-coupling between 
NMR active nuclei results in the NMR signals (peaks) to be split into multiple peaks. The 
number of peaks in the observed NMR spectrum is governed by the total number of 
coupled nuclei – each spin ½ nucleus coupled to n nuclei is split into n+1 peaks. The 
magnitude of the J coupling is determined by: (a) the chemical nature of the coupled nuclei 
(heteronuclear vs. homonuclear), the number of covalent bonds between coupled nuclei and 
the relative orientation between the two coupled nuclei.  
Finally, the dipolar coupling between nuclei is a through space interaction that depends on 
the distance between the two NMR active nuclei, as opposed to covalent connectivity. In 
simple NMR experiments, the dipolar coupling largely contributes to the line width of the 
peaks in the spectrum, since each NMR active nucleus acts as its own magnet and thus 
perturbs the magnetic field of those nuclei around it. The dipolar coupling gives rise to the 
Nuclear Overhauser effect (NOE), the perturbation of the energy state of one spin by 
another through space. 
With simple organic molecules, it is possible to determine the molecular structure using 
one-pulse (i.e. 1H and 13C) NMR experiments. Most organic groups have defined chemical 
shift ranges and, in conjunction with other spectroscopic techniques, the chemical shift and 
J-coupling provide suitable information to determine the molecular structure. For more 
complicated molecules – and especially large biopolymers, the enormous number of nuclei 
results in a complex, highly degenerate and uninterpretable NMR spectrum. The general 
approach to obtain resonance assignments for complex molecules is based upon a technique 
known alternatively as correlation or multidimensional NMR spectroscopy (nD NMR). In 
nD NMR, the NMR interactions, obtained by a suitably designed pulse sequence are 
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displayed along two (n = 2) or more orthogonal axis. For example, the chemical shifts of two 
J-coupled nuclei can be obtained by an NMR experiment that first detects the chemical shift 
of the first nucleus, then allows for transfer between the two nuclei by the J coupling and 
then finally detects the chemical shift of the second nucleus. Alternatively, the same 
experiment can be performed by with transfer arranged via the NOE effect. Then, the 
chemical shifts of all nuclei close in physical space, but not necessarily covalently connected, 
can be obtained. Together, these techniques permit both the assignment of complex organic 
molecules as well as a determination of three- dimensional structure. 
For moderately sized proteins (<= 100 amino acids), homonuclear (2D) 1H-NMR spectroscopy 
provides sufficient information to obtain resonance assignments, secondary and tertiary 
structural constraints suitable for the determination of high-resolution structure (Wuthrich, 
1986). The resonance assignments phase proceeds in two steps. First, individual amino acids 
are assigned using J-coupling experiments to identify coupled sets of spins (spin systems), 
taking advantage of the characteristic proton fingerprint spin topologies of the natural amino 
acids. As there are no strong proton J-couplings between adjacent amino acid, this results in 
exclusively intra-residue assignments. Inter-residue connectivities are obtained via through 
space NOE experiments that allow correlations between protons that are close in space (i.e. on 
adjacent amino acids) but which are not necessarily detectably J-coupled. 
2D-1H spectra of protein encode both distance and angle restraints that can be extracted from 
the spectra. The magnitudes of multi-bond scalar couplings (i.e. the three bond J coupling 
along the peptide backbone between the alpha and amide protons, 3JCH-NH) are a function of 
the intervening angles. The intensity of the cross peaks in 1H-NOE type experiments are 
proportional to the inverse sixth power of the distance between the two nuclei. Additional 
structural information is available from the pattern of chemical shifts that deviate in a regular 
pattern from that of an unstructured peptide depending upon the type of secondary structural 
element they are found in. Furthermore, during the NMR experiment, amide protons from the 
protein backbone can exchange with solvent if not protected by stable hydrogen bond 
formation. If deuterated water is used during the NMR experiment, hydrogens that have 
undergone exchange disappear from the spectrum. Thus, by dissolving the protein in 2H2O, it 
is possible to identify amino acids that are located in regions of stable secondary structure, 
since they are protected from exchange with 2H. The data obtained can then be used to 
compute a family of NMR structures that satisfy the measured constraints.  
The greater number of resonances, and higher molecular weight of larger proteins (which 
results in broader and less well resolved NMR signals) necessitates the use of heteronuclear 
(13C and 15N) multidimensional (nD > 2) spectroscopy for resonance assignments and 
structure to be obtained. Numerous pulse sequences have been developed to obtain 
chemical shifts, scalar couplings and distances using the 15N and 13C chemical shifts to 
provide additional resolution for the spectra. Despite the additional complexity associated 
with performing these experiments (including the need to prepare isotopically labeled 
protein samples), the basic building blocks of structure determination are essentially the 
same as described for homonuclear 1H protein spectroscopy: obtain resonance assignments 
from intra- and inter-residue correlations, determine distance and spatial (angular) 
constraints, incorporate additional parameters such as amide protection and patterns of 
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NMR experiments involve the perturbation of the collection of spins from their equilibrium, 
a process that is opposed by relaxation effects that restore the collection of spins back to 
their equilibrium state. Although spontaneous relaxation is an inefficient process, the 
motion of the protein in solution (both overall tumbling and low barrier transitions) gives 
rise to local magnetic fields that can result in the loss of the NMR signal. In general, there are 
two relaxation processes that are of interest. T1 (transverse) relaxation is the true relaxation 
of the spins to equilibrium state. T2 (longitudinal) relaxation is the loss of NMR coherence 
between two otherwise identical spins in different molecules. Both are a result of global and 
internal protein motions and place limits on the length (and complexity) of a given NMR 
experiment. While great care can be taken to minimize the effects on the NMR spectra (such 
as designing the shortest possible pulse sequences necessary to obtain required information) 
the relaxation processes also provide valuable information both on the overall shape of the 
protein (from tumbling effects) or internal conformational transitions (dynamics). The latter 
information is of increasing importance as it is recognized that proteins, rather than being 
static entities, exist in multiple inter-converting sub-states and that agonists and antagonist 
may function by favoring (or disfavoring) one or more of these states. Site specific 
information on protein dynamics is thus of both basic interest to understanding protein 
function but also of practical interest to the design of improved pharmaceuticals.  
NMR experiments specifically designed to measure protein dynamics have been developed 
(Mittermaier and Kay, 2006). These include the aforementioned amide proton protection 
experiments, since transient opening of the protein structure permits the exchange of 1H 
with 2H which can be directly measured in a 2D 1H,15N J-coupling correlation experiment 
(the heteronuclear single quantum coherence, HSQC experiment) for each amide nucleus in 
the protein backbone and some side chains as well. More quantitative information on 
backbone protein dynamics can be obtained by measuring the T1 and T2, as well as the 1H-
15N NOE. Methods have been developed to interpret these parameters in terms of the 
angular fluctuations and timescales of motion of the protein backbone. Similar experiments 
have been developed to monitor the dynamics of protein side chains using heteronuclear 
relaxation of isotopically labeled side chains.  
Motions slower than that contributing to nuclear relaxation are also apparent in the NMR 
spectrum of proteins. For example, if the protein inter-converts between two or more 
conformations slower than the NMR data is recorded; two sets of resonances will appear in 
the spectrum. When this chemical exchange is faster, a single set of resonances may appear 
but the exchange parameters may be extracted from appropriately designed NMR 
experiments. Because these experiments measure biologically relevant timescale motions 
(s-ms) they are of special interest in understanding protein function, and its perturbation 
by ligand binding (Palmer and Massi, 2006). 
NMR dynamics and exchange experiments are excellent of examples of NMR investigations 
where high-resolution structure determination is not necessarily the key endpoint. Other 
examples include measuring one or more NMR parameters, such as protein 1H and 15N 
chemical shifts in an HSQC experiment as a function of ligand concentration to identify 
binding sites (and in some cases binding constants). These experiments are particularly 
valuable when structure of the biomacromolecule of interest has already been obtained and 
the goal is restricted to identifying novel ligands, ligand variants or the mode of ligand 
binding. This approach, namely measuring a subset of crucial NMR parameters and 
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utilizing previously available information on the structure of the target molecule, is 
employed by many of the studies summarized in this review.  
6. NMR of integrin I domain antagonists 
The I domain from integrin LFA-1 has been the primary objective of numerous 
investigations to identify novel integrin antagonists. This is due both to the critical role of 
LFA-1 in mediating multiple phases of the immune response, as well as the capacity to 
produce large quantities of pure, soluble isotopically labeled protein to exploit the full range 
of tools of structural biology. An NMR structure of the L I domain was obtained using 
assignment and structural determination methods described in the prior section (Legge et 
al., 2000). In general, the topology is identical to that determined by x-ray crystallography. 
Most significantly, the C-terminal helix (7), which shows the greatest variation in 
crystallographic structures, is highly flexible, as determined both by absence of long-range 
1H-1H NOEs, weak 1H-15N NOEs as well as limited protection against amide proton 
exchange, compared to the core of the protein. These observations validate the biophysical 
model and computer simulations of a flexible C-terminus acting as a ratchet or switch 
regulating the conformation and ligand binding activity of the protein (Jin et al., 2004). 
The ligand for L2 is the five-domain cell surface molecule Intracellular Adhesion 
Molecule (ICAM)-1. Titration of a soluble two domain ICAM-1 fragment (sICAM-1-D1-D2) 
into the protein labeled with 15N and / or 15N, 13C revealed unique, concentration dependent 
behavior of the pattern of heteronuclear and proton chemical shifts (Huth et al., 2000). At 
high concentrations of ligand, extensive broadening in the NMR spectrum was observed, 
consistent with formation of a high molecular weight complex. At sub-saturating 
concentrations, however, the broadened residues were largely confined to two regions of the 
protein. Line broadening at residues around the MIDAS could be expected due direct 
chemical exchange with ligands. A second region of greater than average broadening was 
observed in the C-terminal helix and the opposing -strand. The cleft between the two 
secondary structural elements was termed the I domain activation site (IDAS) as the basal 
and inducible ligand binding activity of several holoreceptors bearing mutations in the cleft 
was enhanced when compared to wild-type LFA-1 receptors.  
6.1 Lovastatin  
The allosteric regulation of I domain function by residues in the MIDAS suggests that some 
anti-LFA-1 antagonists may work via  an allosteric mode of pharmacological intervention 
distinct from competitive inhibition. A high-throughput screen for small molecule 
antagonists of LFA-1 identified one such compound, lovastatin, which is the prototypical 
member of a class of small molecule allosteric integrin antagonists (Kallen et al., 1999).  
Lovastatin, a fungal metabolite was earlier identified as competitive inhibitor of a 3-
hydroxy-3′-methyl glutaryl coenzyme A (HMG CoA) reductase, an enzyme in the 
cholesterol biosynthetic pathway and is used clinically for the reduction of high serum 
cholesterol. However, lovastatin also has (potentially) beneficial immunosuppressive 
properties that may be independent of the role in lowering serum cholesterol. Together, the 
observation of immune-modulation properties of lovastatin and its identification in a screen 
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for LFA-1 antagonists suggests that the novel effects may be obtained directly via inhibition 
of LFA-1 (Weitz-Schmidt et al., 2001). 
Using a cell based assay, lovastatin inhibits the adhesion of LFA-1 expressing cells to 
ICAM-1 substrate with an IC50 ~25 M. Using a cell free assay with purified receptor and 
ligand proteins, the IC50 obtained was ~ 2.5 M, demonstrating that the inhibition is a 
property of the proteins and does not involve the HMG-CoA reductase activity. Because 
lovastatin contains a lactone moiety that may be prone to hydrolysis, it was hypothesized 
that direct coordination of lovastatin acid to the MIDAS as the mechanism of inhibiting 
LFA-1 / ICAM-1 adhesion. Contrary to this suggestion, the hydroxyacid has weaker 
inhibition potential (>100 M and ~14 M for the cell based and cell free assays, 
respectively).  
The mechanism of lovastatin inhibition of LFA-1 was directly addressing using soluble I 
domain labeled with 15N using an E. coli expression system (Kallen et al., 1999). 1H,15N 
HSQC spectra were obtained for the free protein and in the presence of increasing 
concentrations of lovastatin-lactone or lovastatin-hydroxyacid. When the chemical shift 
differences between the free and drug added forms are mapped onto the structure of the I 
domain, a clear pattern became evident. The most significant perturbation in chemical shifts 
both in intensity and position are in the crevice between the C-terminal helix and the 
opposing beta sheet. Computer simulations further support the conjecture that lovastatin, 
and its derivatives, act as allosteric antagonists of LFA-1 function, preventing the obligate 
downward motion of the C-terminal helix (Gaillard et al., 2007).  
A family of related statin derivatives was subsequently screened for binding to the I domain 
using a 1H,15N – HSQC . By obtaining spectra as a function of ligand concentration (with 
fixed protein) it is possible to estimate the binding dissociation constant (KD) between statin 
derivative and I domain. The KDs range from ~2.0 M for lovastatin and simvistatin to ~ 8 
M for mevastatin. Previstatin, with a hydroxylated terpenoid ring has an KD > 100 M, 
presumably due to the energetic costs of burying a polar residue in the largely hydrophobic 
crevice. The tightest binding inhibitor identified by NMR in this study was the synthetic 
derivative LFA703, which bound with ~0.2 M affinity. Most significantly, these changes in 
KD directly parallel the IC50 measured in using the intact holoreceptor in cell based 
assays, demonstrating that the I domain is the principle, and likely exclusive, source of 
the inhibitory effect and that screening allosteric antagonists by binding to isolated I 
domains is a valid approach to determining the affinity, and indirectly the efficacy, of I 
domain allosteric antagonists. Also, although the dynamics of the I –domain / lovastatin 
complex was not quantitatively measured, the spectra all showed signs of conformational 
exchange, consistent with fast binding and release kinetics of lovastatin or its derivatives 
from the I domain.  
The demonstration of potent allosteric inhibition of the I domain has driven additional 
screens for LFA-1 antagonists derived from alternative chemotypes. One successful cell 
based screen identified a diaryl sulphide with an IC50 of ~2.3 M, comparable to lovastatin 
(Crump et al., 2004). The addition of drug to 1H,15N labeled protein results in chemical shift 
and intensity changes in the spectra (due to chemical exchange) that were analogous to 
those for lovastatin, demonstrating that the two dissimilar chemotypes utilized a common 
mechanism for inhibition of function. Additional synthetic diaryl sulfides were prepared 
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and also shown to bind to the same position of the I domain, albeit with dramatically greater 
efficacy (IC50 ~44 nM). Unlike lovatatin and the parent compound, however, no chemical 
exchange broadening was observed in the spectrum, consistent with tighter binding of the 
derivative; this indicates that the improved efficacy is a function of better binding to the I 
domain, as opposed to acting on a second site on the intact receptor.  
Although the HSQC spectra are a rapid means of identifying and characterizing 
compounds that bind to the I domain, the process of drug design is greatly enhanced by 
having a high-resolution structural model of the drug – protein complex. Towards this 
aim, a comprehensive study of an I –domain allosteric inhibitor complex to the I domain 
was undertaken, initially with the determination of the 1H, 15N and 13C chemical shifts 
assignments of the full complex. The authors subsequently obtained multiple NOE 
distance based constraints between drug and protein, facilitating a high-resolution 
structure of the complex that could be used to rationalize the enhanced efficacy of the 
drug. As expected, the parent compound binds within the IDAS with a pocket formed by 
strands one, three and four of the central beta sheet and helices one and seven. Excellent 
superposition of the model with a crystal structure of the I domain – lovastatin complex 
validates the principle of using distinct molecular scaffolds to identify optimal allosteric 
inhibitors of I domain function.  
6.2 SAR by NMR 
Structure activity relationships by NMR (SAR by NMR) is an NMR based screening 
technology for discovering de novo or enhanced variants of existing protein inhibitors 
(Shuker et al., 1996). A library of small molecules is screened for binding to a protein target, 
typically by monitoring chemical shifts in a 1H,15N HSQC experiment. Although most small 
fragments in the library bind to protein weakly, when joined synthetically the binding 
affinity and hopefully, efficacy of the composite molecule is improved dramatically. SAR by 
NMR may be used to identify completely novel combination of appropriate molecular 
fragments. Alternatively, the approach can be used to selectively enhance the affinity of one 
segment of a small molecule while leaving another fixed. In this context, the invariant 
moiety is added first to the NMR tube; subsequently, a library is screened to find 
appropriate binders with enhanced binding potential at the variable portion of the molecule. 
Finally, the novel molecular fragment is tethered synthetically to the fixed portion and the 
molecule is tested for the desired biological activity.  
SAR by NMR was used to successfully improve the binding and efficacy of inhibitors based 
on an aryl cinnamide moiety (Liu et al., 2001; Winn et al., 2001). After identifying fragments 
that could potentially improve the inhibitor, the authors next obtained 1H-1H NOEs of the 
ternary complex. The introduction of this additional step was a significant advance over 
simpler NMR screening protocols since it was possible to conclusively demonstrate that 
both fragments could bind to proximate but distinct regions on the protein. This extra step 
validated the potential of the separate fragments to mutually enhance protein binding when 
synthetically fused. These efforts led to the identification of a number of LFA-1 inhibitors 
with EC50s between 20 and 800 nM. In several cases the enhanced affinity was much less 
than anticipated based on the estimated binding affinity of the two fragments. However, 
this is not an unexpected phenomena since the linkers can both directly, through 
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interactions with the protein, and indirectly, by forcing unfavorable orientation/steric 
effects on the protein, lower the combined binding potential of the linked fragment with 
respect to that of the individual chemical moieties.  
6.3 Peptides 
Peptides, with sequences derived from the canonical binding protein ligand are an 
alternative source of integrin binding reagents. Generally, short peptides are unstructured in 
aqueous solution. Cyclization of the peptide through the backbone or appropriate side chain 
chemistries enhances the population of one or more structured states. Artificial non- 
genetically encoded amino acids are also introduced into the sequence as structural 
promoting agents or to add additional side chain chemistries.  
Peptides, however, are particularly difficult to crystallize, particularly from aqueous 
solution. Also, crystal structures of small molecules and peptides are modulated by strong 
packing forces and the observed structure may be different from that in free solution or 
bound to a target protein. NMR spectroscopy can capture the full range of conformations 
sampled by the peptide and in appropriate systems, such as the I domain, also permits 
direct observation of both receptor free and receptor bound forms.  
Two cyclic peptides, cIBR, derived from ICAM-1 12-21, (Cyclo1,12-Pen-PRGGSVLVTGC-OH) 
and cIBC, derived from ICAM-16-15, (Cyclo1,12-Pen-PSKVILPRGGC) have been shown to 
inhibit homotypic and heterotypic cell adhesion mediated by LFA-1 in a concentration 
dependent manner (Anderson et al., 2004). The peptides were cyclized through disulphide 
formation between the penicillamine moiety in position one and the cysteine at position 
twelve. Both peptides work, at least in part, via interactions with the I domain since their 
binding can be inhibited by the anti-L-I domain antibody R3.1. Direct binding to intact 
soluble, TM free LFA-1 was demonstrated using a colorimetric ELISA binding assay. It is 
critical to note that although both peptides are derived from the authentic ligand, neither 
contains the canonical acidic group (in this case Glu34 of ICAM-1), suggesting an alternative 
mode of inhibition.  
The structure of cIBR was determined by NMR spectroscopy in aqueous solution (Gursoy et 
al., 1999). The resonances were assigned using conventional through- bond (J-mediated) 2D-
1H NMR spectra and inter-residue correlations from NOESY type experiments which were 
also used to obtain distance based constraints. Technically, the authors used a related pulse 
sequence called ROESY, a pulse sequence more suitable for obtaining distance constraints in 
low molecular weight systems. One experiment was performed to obtain the 3JNH-HC 
constants, another to determine the temperature dependence of the amide proton chemical 
shifts that are related to hydrogen bonding strength and thus indicative of presence of stable 
secondary structure. Molecular dynamics was used to obtain a set of structures for 
structural analysis. During the simulation, all the peptide bonds except the first (between 
Pen-1 and Pro-2) were held in the trans conformation. Final analysis of the structural 
ensemble revealed that a cis-conformer was present, albeit at low population and this form 
was not further studied. 
Interactions between proximate amide protons observed in the ROESY spectrum suggest as 
many as 3 -turns about Pro2-Gly5, Gly5-Leu8, and Val9-Cys12 in the peptide structure, 
although it is unclear of all three turns are present in the structure simultaneously or are 
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inter-converting on a timescale slower than the NMR experiment. Additional data, namely 
the temperature dependence of amide protein chemical shift, suggests that the hydrogen 
bonds are weak and the structures are transiently populated. 
In total, six structural families were obtained consistent with the NMR data, with each 
family containing 20 structures. Remarkably, some of the structures in the ensemble are in 
good agreement with the sequences in the context of the full-length domain 1 of ICAM-1. 
For example, the Pro-Arg-Gly-Gly sequence is derived from the -hairpin turn connecting 
strands A and B of domain 1 of ICAM-1. Other regions of structural homology were also 
identified between peptide and full length protein, demonstrating that the small, cyclized 
peptide has captured at least some of the authentic architecture of the full-length ligand.  
The binding site of both ICAM-1 derived peptides was measuring using the perturbation in 
2D-NMR heteronuclear chemical shifts approach previously described. As anticipated by 
the absence of an acidic group in the ligand, the NMR data suggest an alternative, allosteric 
mode of inhibition for the two peptides. Specifically, the binding site was identified as the 
IDAS, the binding pocket for small molecule antagonists (Zimmerman et al., 2007).  
Although high resolution structural data was not obtained, the authors utilized the existing 
peptide structures, as well as the known structure of the I domain, to dock the peptides 
individually into the IDAS performing energy minimization to obtain a structural model 
which could reveal key interactions between peptide and protein. Intriguingly, despite 
being of entirely distinct classes of chemical moieties, it was possible to superimpose 
segments of the peptide on the known position of the lovastatin. The superposition revealed 
that common amino acids in the I domain contact the two distinct types of inhibitor. The 
model of the peptide – I domain revealed that, much like lovastatin, the hydrophobic 
residues of the peptide Gly 5- Gly 11 of cIBR are buried into the crevice with numerous 
hydrophobic contacts between the apolar core and the peptide. In general, the polar 
peptide regions of the peptide are exposed to solvent; however there is a putative salt 
bridge interaction between the arginine residue and Glu301 of the protein. Future high 
resolution studies will be required to provide important insight into the mechanism of 
recognition between peptide and I domain, the role of the flexible, hydrophilic peptide 
sequence in inhibiting integrin function, and to rationalize the superior performance of 
cIBR over cIBC as an LFA-1 antagonist. However, the cyclic ICAM-1 peptides were first 
designed using the rational that competitive antagonists could be obtained using 
appropriately constrained elements of the native ligand sequence. These studies then 
demonstrate the power of basic, readily accessible NMR technology to test and refute 
mechanistic hypothesis of integrin antagonism.  
6.4 Volatile anesthetics 
General anesthesia is administered to ~40 million patients undergoing surgery in the United 
States every year (Suttner et al., 2002). Volatile anesthetics (VAs), a group of lipophilic small 
molecules that induce general anesthesia, are a major component of the anesthetics drugs 
currently used in operating rooms worldwide. Nevertheless, our understanding of the 
mechanisms by which these small-molecules alter the activity of the CNS, thereby leading to 
the loss of consciousness, remains limited. The established molecular targets of VAs in the 
CNS include membrane-embedded ion channels; e.g.,-aminobutyric acid (GABA) type A 
receptors, two-pore-domain potassium channels, and N-methyl-D-aspartate (NMDA) 
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receptors. The aggregate of biochemical evidence suggests that VAs modulate ion channel 
functions in an allosteric, as opposed to a competitive, manner (Hemmings et al., 2005). The 
lack of high-resolution structural information regarding ion channels has made it impossible 
to determine the exact VA binding site(s) or mechanisms at work.  
A unique feature of volatile anesthetic drugs is that the blood concentration at which these 
drugs exert pharmacological activities (i.e., induction of general anesthetic states) is high (0.1 
to 1 mM). At these concentrations, anesthetics have been reported to affect not only 
neuronal cells but also diverse types of cells including leukocytes, platelets, endothelial cells, 
myocardial cells, bronchial epithelial cells, and cancer cells (McBride et al., 1996). Therefore, 
these secondary effects of VAs are of enormous clinical relevance and concern. 
We investigated integrin interactions with volatile anesthetics for three reasons (Yuki et al., 
2010; Yuki et al., 2008). First, we rationalized that the promiscuous nature of VA – protein 
interactions, in conjunction with the important role of LFA-1 function in the immune system 
made the protein a potential candidate for modulation by VA. Second, the I domain is a 
well-characterized, soluble protein amenable to biophysical and structural analysis. Beyond 
the direct physiological relevance of LFA-1 : VA interactions, we viewed the I domain as an 
ideal model system to understand how weakly binding VA could modulate protein 
function. Finally, the availability of NMR techniques would allow us to obtain a molecular 
mechanism for our observation that two volatile anesthetics, isoflurane and sevoflurane act 
as antagonists of LFA-1 binding to ICAM-1, both in cell and cell- free assays. NMR 
spectroscopy has been utilized in earlier studies of VA : protein interactions and 
demonstrated that it is possible to identify VA binding sites on proteins using NMR 
(Yonkunas et al., 2005). A critical difference between our studies and earlier investigations, 
is in the ability to perform activity assays on the I domain and directly compare anesthetic 
interactions with effect on biological functions. Previous studies have utilized model 
proteins that lack catalytic or adhesive activity and such comparisons were unavailable.  
To map potential isoflurane binding site(s) in the LFA-1 I domain, we utilized heteronuclear 
1H,15N-HSQC-NMR spectroscopy, an established technique for the identification of small-
molecule interaction sites on isotopically labeled biomolecules, including anesthetic 
interactions with soluble protein domains (Yuki et al., 2008). An overlay of two HSQCs 
taken at the endpoints of an isoflurane titration (0 and 12 mM isoflurane, because high 
concentrations are preferred in order to fully occupy the binding site) not only revealed that 
a number of resonances undergo shifts in resonance frequency, but also identified the LFA-1 
I domain as a potential binding site for isoflurane. The chemical shift of most residues was 
unchanged whether at the lowest (0 mM) or the highest (~12 mM) concentration of drug 
However, several resonances, such as threonine 291 at top the loop that connects to the C-
terminal helix, underwent a dose-dependent shift in resonance frequency, indicating an 
interaction and/or change in the electronic environment or local structure of the protein.  
The magnitude of the isoflurane-induced shift was mapped onto the sequence and 
secondary structure (FIGURE 3). Significant chemical-shift perturbation occurred in six 
regions of the protein sequence: 1) the N-terminal segment; 2) the C-terminal portion of 1; 3) 
the loop between 2 and 3; 4) 3; 5) 5; and 6) the C-terminal segment incorporating 5-7. 
Residues perturbed by the addition of the LFA-1 I allosteric antagonist lovastatin (visible as 
a uniform yellow background, FIGURE 3) showed a good correlation with those by 
isoflurane. The largest deviation in chemical shifts occurred with the aromatic resonances  
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Fig. 3. NMR spectroscopy to study isoflurane-binding site(s) in the LFA-1 I (A) Scaled 
chemical-shift perturbation of 12 mM isoflurane mapped onto the LFA-1 I domain protein 
sequence and secondary structure. (B) Structure of the LFA-1 I domain  showing amide 
nitrogen residues affected (ppm = 0.05 ppm) by the addition of 12 mM isoflurane. Gray 
represents residues unperturbed by isoflurane while red represents residues that met or 
exceeded the threshold for perturbation. Helices and strands are labeled. Residues T291 
(red) and S245 (green) are labeled. The yellow spheres represent the Mg2+ ion at the ICAM-1 
binding site, termed the metal ion-dependent adhesion site (MIDAS). Note that the residues 
near the MIDAS were not affected and that the affected residues clustered near the cavity 
formed between the 1 and 7 helices and the central  strands. This figure was adopted 
from Yuki et al. 2008. 
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phenylalanine 153 (F153) and tyrosine 307 (Y307), which could indicate a direct interaction 
between the halogenated hydrocarbons and the aromatic moieties, as previously suggested. 
We note that Y307 is also an interacting residue in the derived model of cILB peptide with 
theI domain, suggesting a common mechanism of inhibition by the two remarkably 
different chemotypes. To generalize these results to other VA, we performed the same 
experiment using the VA sevoflurane (Yuki et al., 2010). Sevoflurane induced chemical shift 
perturbation in a subset of residues located at the C-terminal portion. This is consistent with 
the NMR data that we previously obtained from isoflurane's interaction with the LFA-1 I 
domain thereby suggesting that sevoflurane also binds to the C-terminal portion of the LFA-
1 I domain, in which it blocks LFA-1 in the same allosteric manner that isoflurane does. By 
contrast, propofol, a distinct class of VA, induced perturbations to many residues spread 
over the I domain. The data is consistent with the idea that a high concentration of propofol 
inhibits LFA-1 in a mixed competitive and allosteric manner (NSA and MS, unpublished). 
7. Saturation-Transfer Difference NMR (STD) and transferred NOE NMR 
studies 
One of the central challenges faced in the study of integrin- antagonist interactions, 
particularly in the study of agonists which may interact with integrin domains that can-not 
be expressed in isolation such as the - I like domain, is to determine the structure of the 
ligand bound complex. While docking and modeling studies, such as those described above, 
are valuable, changes in the conformation of the ligand and receptor can contribute to 
uncertainty in the molecular nature of complex formation. Saturation transfer difference 
NMR spectroscopy (STD-NMR), a technique originally developed to identify the 
carbohydrate epitope of protein lectins, has emerged as a powerful approach to overcome 
this difficulty (Mayer and Meyer, 1999). Because STD-NMR can be performed on proteins 
expressed in the native environment and does not require substantial quantities of protein, it 
is ideally suited to studying the interaction of cell surface transmembrane receptor 
interactions with potential antagonists. In fact, the high molecular weight of integrin in cell 
membranes – and even within cells – is advantageous since the saturation transfer effect 
improves with the molecular weight of the complex. 
STD-NMR is based on the NMR effect of saturation. Prolonged irradiation of one or more 
spins by a long pulse or pulse train results in loss of signal intensity from the spectra of the 
irradiated spin. This saturation can propagate to neighboring spins through the dipolar 
interaction; the kinetics of the spread is favored in systems with high molecular weight. 
Because the transfer effect is through the dipolar coupling, the nuclei do not need to be 
covalently joined on the same molecule for saturation to spread between the spins. Thus 
saturation will result in the loss of signal intensity both for irradiated peaks and those 
spatially proximate. The saturation time can be manipulated to allow for propagation to 
proximate as opposed to distal spins, allowing for the mapping of direct binding epitopes 
between high-molecular weight protein systems and their ligands.  
The STD-NMR experiment requires two sequential NMR spectra be obtained – one with and 
one without saturation. Because the experiment is performed with a large excess of ligand 
over protein, the saturation free spectrum is effectively identical to the spectrum of the free 
ligand. The high molecular weight of the membrane preparations or cells renders them 
undetectable by solution NMR. The second spectrum is acquired with saturation pulse(s) 
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applied selectively to a protein resonance. The saturation is then transferred to the ligand 
from the protein by the dipolar coupling. If the two spectra are subtracted, the difference 
spectrum only contains peaks from ligand resonances that were in contact with the protein 
during the saturation period. The STD effect is useful for characterizing protein-ligand 
complexes with weak-moderate binding constants (KD ~ 1X10-3 - KD ~ 1X10-8). This 
technique can be used to both validate the specificity of a binding interaction and map the 
epitope of nuclei that are directly bound to the protein since they undergo the greatest 
saturation effect.  
STD-NMR was first applied to the study of cyclic-RGD peptides binding to purified IIb3 
integrin reconstituted into liposomes (Meinecke and Meyer, 2001). Using STD-NMR the 
authors determine an affinity KD of 30-60 M for the peptide cyclo(RGDfv) complex with 
reconstituted integrin. No saturation effect was observed for liposomes free of integrin or 
non-ligand peptides with integrin containing liposomes, validating the specificity of the 
approach. Furthermore, a mixture of linear and cyclic RGD peptides gave rise only to 
spectra of the cyclic peptides, consistent with a previously established greater affinity for the 
cyclic versus linear peptide analogs. Analysis of the spectra and concentrations allowed for 
an estimate of ~1mM for the KD of the linear peptide. By comparison, the linear RGDS 
peptide, with a known KD of 55 M was shown by STD-NMR to be an effective competitor 
of the cyclic-RGD peptide.  
The authors further mapped the binding epitope of the peptide using the intensity of the 
resonances as a measure of proximity to the proteins surface. The largest signals were from 
the aromatic proteins of the D-Phe followed by the Arg H, ArgH/H, Asp H and the -
proteins of the unnatural amino acid D-Hph residue as well as the -protons of Val, the H 
protein of Gly, demonstrating that these were the atoms directly contact with integrin. Prior 
studies on the conformation of the RGDfV cyclic peptide in DMSO by 2D-NMR structural 
methods was used to interpret the epitope mapping investigation (Aumailley et al., 1991). In 
the NMR structure, the side chains of Arg, Asp and Val are disposed perpendicular to the 
plane of the peptide and point to one side. The D-Phe side chain is located in an equatorial 
conformation. These suggest that the ligand interactions on one side of the peptide ring with 
the Phe in the equatorial position making further stabilizing interactions. The pattern of the 
Arg alkyl side chain suggests that strongly hydrophobic interactions are predominant while 
the Arg -protons, which would be indicative of the tight interaction of the guanidine 
group, are only weakly saturated. Although this is at first surprising, given the conservation 
of the Arg in the canonical binding motif, the L-amino acids norleucine, cyclohexylglycine, 
norvaline, tert-leucine and 4-hydroxyproline all have tighter affinity in the position 
occupied by Arg that the Arg itself, suggesting that the ionic interaction makes little or no 
contribution to the stability of the complex. Also, the high intensity of the D-Phe resonance 
is consistent with the fact that hydrophobic and aromatic residues that are adjacent to the 
Asp have greater inhibitory potential, both in natural disintegrin proteins and designed 
inhibitor peptides. This effect is exploited in IIb3 specific platelet inhibitors including the 
cyclic hepta-peptide eptifibatdide, which has a L-homoarginine in the first position 
(Scarborough et al., 1993). Thus the extended alkyl chain in the first position and the 
aromatic in the fourth position of this optimized IIb3 inhibitor are both consistent with 
the results of the STD-NMR studies of the binding epitope.  
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A comparison between STD-experiments obtained on liposomal preparations with IIb3 
on the surface of platelets was obtained with interesting results (Claasen et al., 2005). 
Although the binding epiotpe in the two experimental contexts is almost identical (with 
minor variations) the STD effect was much higher in the intact platelet preparation, despite 
the fact that the concentration of receptor in the liposomal sample is ~ 5 M and only ~0.6 
M for the platelet sample, demonstrating the affinity, of IIb3 for the ligand is 
significantly higher in the native context. This demonstrates the great utility of STD –NMR 
that can determine both epitopes and approximate measure of antagonist affinity on intact 
cells. Assuming 150,000 receptors/cell, 108 or fewer cells are required to obtain an STD-
NMR spectrum with good signal to noise, a number that can readily be accommodated in a 
standard NMR tube.  
A powerful feature of the STD-NMR experiment is consequently the ability to obtain 
binding information directly on the cells targeted by a therapeutic agent of interest 
(Potenza et al., 2011). One such study examined the binding of two closely related cyclic-
RGD peptides with dramatically different IC50s to the integrin V3 on EVC304, a 
bladder cancer cell line. The two cyclic peptides, with competitive IC50s of 6.4 nM versus 
154 nM against echistastin binding differ in the configuration about two stereo-centers 
and are known, from earlier NMR studies of the free inhibitor, to have distinct 
conformations in the unbound state. The STD-NMR derived epitope of the stronger 
binding cyclic-peptide that has a M IC50 for inhibiting cell adhesion to ECM ligands 
agrees with a previously derived docking model. The ligand interacts through a pair of 
ionic interactions (Arg-guandinium with V-Asp218 and Asp-carboxyl with the 3-
MIDAS), a - interaction (between a benzylic group on the ligand and an aromatic ring 
of 3-Tyr122) and an extended network of hydrogen bonds including the Asp-NH and 
C=O of 3-Arg216. The overall structure of the cyclic peptide closely resembles the high-
resolution crystal structure of the peptide cingletide bound to V3.  
The authors used a second technique, transferred NOE (TR-NOE) spectroscopy, to obtain 
the conformation of the bound ligand. TR-NOE is an NMR experiment that permits the 
selective observation of ligand NOEs through space correlations present in the low 
population bound form of a complex to be observed in the high population free state. Using 
this technique, it was possible to identify conformational changes in the ligand that are 
required for ligand binding.  
STD-NMR of the weaker binding cyclic peptide was also obtained using STD-NMR and 
revealed a distinct binding epitope. The most significant change, due to the altered 
conformation around the two stereocenters, was the loss of the hydrogen bonding network 
between ligand Asp and the -subunit. The authors also using TR-NOE observed 
conformational changes between the ligand in the free and bound state. The bound 
conformation of the second inhibitor forms less favorable contacts with the integrin, 
accounting for the loss of inhibition efficacy.  
One important extension of the STD-NMR experiments is the incorporation of heteronuclear 
2D detection, which is required to determine the epitope of more complex peptides and 
proteins that would otherwise be difficult to study due to resonance overlap (Assadi-Porter 
et al., 2010; Wagstaff et al., 2010b). A recent investigation both demonstrated both the overall 
utility of STD-NMR for study of integrin-antagonist interactions and also the advantages of 
using 2D NMR to as opposed to 1D detection despite the added time and expense of 
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preparing the requisite isotopic labeled sample(s). The authors studied a complex of V6 
with a peptide inhibitor derived from the surface loop of the foot and mouth virus capsid 
protein, which utilizes this integrin as a receptor. The peptide, A20FMDV2, has the sequence 
NAVPNLRGDLQVLAQKVART. Previous work showed that peptide inhibitors of V6 
utilize the extended sequence DLXXLRGD as an extended recognition motif. To obtain the 
isotopic labeled peptide, the authors utilized a commercial E. coli fusion peptide system 
whereby the peptide is fused to the insoluble ketosteroid isomerase protein with a 
methionine residue introduced between KSI and the peptide sequence. The insoluble fusion 
pair is readily separated from the soluble cell material and then can be cleaved using 
cyanogen bromide treatment (Wagstaff et al., 2010a).  
The 2D-13C STD-NMR experiments demonstrate a pronounced contribution from the 
DLXXL motif to the binding epitope and, surprising, a less substantial component from the 
RGD regions. Significantly, an earlier 1D-STD-NMR misidentified part of the binding 
epitope, due to uncertainty in the resonance assignments that occur due to overlap in the 
NMR spectrum. The primary interaction between peptide and protein is through 6Leu,  
12Val and 13Leu. Despite not obtaining any high resolution (i.e. NOE or J-coupling) 
constraints, the authors were able to utilize intensity and phase information (both sensitive 
to the saturation transfer efficiency) of resonances from the 1H-13C and 1H-15N detected STD-
NMR experiments to construct a refined model of the peptide-integrin interaction which is 
of great utility in the design of novel peptide and peptide-mimetic inhibitors.  
8. Conclusions 
To build upon the advances described in this review, we have identified five critical areas 
which we feel will contribute to a greater understanding of the mechanism of integrin 
activation and the development of improved antagonists targeting integrin function.  
Automation: Conventional NMR spectroscopy requires the determination of resonance 
assignments to extract meaningful spectroscopic data. The process of resonance assignment 
is, however, manually intensive and cumbersome, especially given the need to screen large 
number of potential binding reagents to a molecular target. There has, however, been recent 
progress in automating the assignment and structure determination and analysis process 
(Guerry and Herrmann, 2011). In particular, methods which permit partial assignments of 
putative ligand binding interfaces without resorting to total assignment or structure 
determination would greatly facilitate the utility of NMR as a high-throughput screening 
tool. One recent advance in this area applied to the development of integrin antagonists is 
the technique of Methyl Scanning. Because many I domain inhibitors contain aromatic rings 
that can induce large chemical shifts in proximal aliphatic side chain resonances, partial 
assignments of methyl carbons and protons can serve as a useful source of constraints 
probing ligand binding to suitable protein pockets. This technique was recently employed to 
study the mechanism of a tight binding (18.3 nM)  arylthio allosteric inhibitor of the LFA-1 I 
domain (Constantine et al., 2006).  
Expression and Labeling: Although the I domain can be produced in isolation of other integrin 
domains using standard E. coli expression systems, other critical integrin domains require 
domain- domain interactions for correct folding. This precludes the use of basic E. coli 
expression systems that are optimal for preparing the isotope labeled samples used in high 
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resolution NMR studies. Recent advances in two areas promise to break though this 
bottleneck. First, the use of eukaryotic expression either in yeast or mammalian cells has 
been demonstrated to produce quantities of protein suitable for NMR studies. In vitro 
translation systems have also been optimized to produce suitable quantities of isotopic 
labeled proteins and represent a viable alternative approach to producing complex 
multidomain proteins of eukaryotic origin (Yokoyama, 2003).  
Transmembrane and cytoplasmic domains: Separation of the transmembrane and cytoplasmic 
domains is a critical step in integrin activation. While existing integrin modulators work by 
stabilizing the inactive conformation of the ecto- domains, there has been recent interest in 
pharmacological targeting of transmembrane structure (Shandler et al., 2011). However, 
transmembrane domains pose a particular challenge for conventional solution NMR due to 
the large molecular weight of the bilayer required to maintain the protein in the correct 
conformation. Recent advances in solution NMR, particularly the development of 
membrane nanodiscs that preserve the authentic structure of the native bilayer, have begun 
to overcome this limitation and provide detailed, high-resolution structural details on 
association of transmembrane peptides (Warschawski et al., 2011).  
Dynamics: While the role of protein dynamics in protein function, and inhibition have been 
widely appreciated, there has been renewed development in methods that can obtained 
with site-specific resolution. A major existing challenge is the incorporation of dynamics 
information into docking and screening protocols. In this area, improved computational 
protocols will be needed to parallel the increased ability to observe and quantify chemical 
exchange processes in proteins. New methods for incorporation of dynamics data into drug 
discover protocols will likely be of comparable importance to the introduction of structural 
constraints (Lin, 2011; Salsbury, 2010).  
Crystal Structures: Paradoxically, the most urgent need in the area of NMR based integrin 
drug design is for additional crystal structures both of new integrins as well as drug – 
integrin complexes. While NMR is a powerful structural tool in its own right, the true power 
of NMR lies in the capacity to rapidly determine structural and dynamic information of 
ligands and their binding sites that can be integrated with existing structures using 
computational modeling tools. The most successful future structure based design 
approaches are likely to integrate multiple sources of information to identify the most 
optimal drug candidates for biological screening.  
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